Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s Scientific Advisory Board, will deliver a keynote presentation at The End in Mind virtual conference being held on October 14, 2021. In addition, Anthony Back, M.D., a member of Reset Pharma’s Scientific Advisory Board, will participate in a panel discussion, Caring for Frontline Workers.
The End In Mind is a virtual conference featuring thought leaders who will discuss the future of psychedelic medicines for those facing serious illness. The event includes academic researchers, policy makers, patients, clinicians, entrepreneurs, and more. To learn more, or to register for the event, visit: https://endwellproject.org/the-end-in-mind/.
- Event: The End in Mind
- Keynote: Meaning Making, What The Research Shows
- Presenter: Stephen Ross, M.D.
- Date: October 14, 2021
- Register: https://endwellproject.org/the-end-in-mind/
About Reset Pharmaceuticals, Inc.
Reset Pharma is a privately held biotechnology company developing and commercializing novel psychedelic treatments for patients with life-threatening illnesses, including cancer. The company’s lead program initially focuses on developing psilocybin to treat severe demoralization in patients with life-threatening cancer. These patients have clinically relevant levels of demoralization with a perceived lack of control, hopelessness and helplessness and an increased risk of suicide. Some of these patients also have anxiety and depression. While the primary focus is the development of psilocybin for demoralization, as there are currently no effective treatments for this disorder, psilocybin also shows promise as a treatment of anxiety and depression in cancer patients. Reset Pharma has established a highly experienced biotech development team and has a Scientific Advisory Board of leading experts in psychiatry, oncology and psychedelics. Information about Reset Pharma can be found at www.resetpharma.com.
This press release contains “forward-looking statements” concerning the development and commercialization of Reset Pharmaceuticals’ products, timing of clinical trials, the company’s business development efforts and its expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements, including the ability to obtain funding to support planned clinical activities. These statements are made as of the date of this press release. Actual results may vary. Reset Pharmaceuticals undertakes no obligation to update any forward-looking statements for any reason.
Reset Pharma Contact